Biochemical and molecular mechanisms of action of bisphosphonates.
about
Interventions to prevent steroid-induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophyManagement of chronic pain in osteoporosis: challenges and solutionsBisphosphonate therapy in pediatric patientsUpdates on mechanism of action and clinical efficacy of risedronate in osteoporosisApoptotic osteocytes and the control of targeted bone resorptionAmerican Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures.Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseasesDiscovery of Novel Allosteric Non-Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthase by Integrated Lead FindingA General Strategy for Targeting Drugs to BoneCalcitonin inhibits SDCP-induced osteoclast apoptosis and increases its efficacy in a rat model of osteoporosisEndocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compoundExperiments and synthesis of bone-targeting epirubicin with the water-soluble macromolecular drug delivery systems of oxidized-dextran.Investigational drugs for fracture healing: preclinical & clinical data.Atypical femoral fractures after anti-osteoporotic medication: a Korean multicenter study.Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans.Clodronate exerts an anabolic effect on articular chondrocytes mediated through the purinergic receptor pathway.Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis.Enhanced Osteogenic Differentiation in Zoledronate-Treated Osteoporotic Patients.Osteoclasts: more than 'bone eaters'.Novel therapeutic targets in myeloma bone disease.Vγ9Vδ2 T lymphocytes activation in osteoporotic patients treated with bisphosphonates.Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cellsZoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function.Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancerLiposome encapsulated zoledronate favours M1-like behaviour in murine macrophages cultured with soluble factors from breast cancer cells.Depletion of spleen macrophages delays AA amyloid development: a study performed in the rapid mouse model of AA amyloidosisImpaired prenylation of Rab GTPases in the gunmetal mouse causes defects in bone cell function.Breast cancer medications and vision: effects of treatments for early-stage disease.Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease.Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice.Alteration of Type I collagen microstructure induced by estrogen depletion can be prevented with drug treatment.The mevalonate pathway in C. elegans.Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor κB ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading.Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.Effects of combined alendronate and alfacalcidol on prevention of fractures in osteoporosis patients: a network meta-analysis.Near IR fluorescent conjugated poly(ethylene glycol)bisphosphonate nanoparticles for in vivo bone targeting in a young mouse model.Bisphosphonate-adsorbed ceramic nanoparticles increase bone formation in an injectable carrier for bone tissue engineering.The effects of lung and prostate cancer bone metastasis on serum osteoprotegerin levels: a meta-analysis.Human stromal cells are required for an anti-breast cancer effect of zoledronic acid.Equilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats.
P2860
Q24198280-AC545801-0148-4F02-ACD3-A28D3044BB16Q26751333-B2263110-6A5E-4D5B-88A7-4E7DBFE5E8B8Q26830702-795B3476-B1D7-4C8B-A39F-0E75B2D1C03FQ26864549-08CDAA70-2F1B-46A7-9D77-199E872563BAQ27023670-1B473606-4BB4-4186-94A4-4B791A0E282EQ27027254-571B89A8-AE58-41BF-ADF5-22D8B67D615EQ27314920-09BD472F-AA36-44FE-9BD6-310CABC834BBQ27702178-FFA8ACF5-C495-44BD-BA23-406CC14BB562Q27702282-45950D41-DA9F-4EEE-808B-9138EF48D0AAQ28481154-F4BBB763-3E52-43D9-A0E4-8C5A81BD862EQ28543939-C55E6424-6283-4987-B064-A8F160DF1243Q30729687-B0F2C67D-E59D-4E63-B0DF-0233B1EA414FQ31052456-81FFFCFE-0875-4718-B409-AFD2D76AA6F7Q33681406-645CAD71-61CF-4970-BF19-AA61AAF66B18Q33716678-2F58FD11-A42B-48FE-9343-BB2E73A2F890Q33750999-057B7193-E49E-447C-9A75-C7A5C2824962Q33771321-48217E2F-211D-49D2-95B6-070695084303Q33838933-387D73BC-4B9D-48A6-9A51-1EB089ADE1A8Q33993757-CA6B7398-F19A-479D-8F6D-EAB633FF7248Q34025065-2242EA8A-8FF9-4F60-AF92-E8CDD2521D3FQ34230320-44D94593-863C-4F23-8422-38F14B167F46Q34358196-38283E0B-DE62-49D7-8FF1-39489C360702Q34505560-766C2145-EA27-4EAA-8C28-F818DB60ED8CQ34945422-C70681B8-0C0E-400C-BF54-CA3FBA00E5D2Q35008733-411A4189-FE2A-4010-B899-7018305C8879Q35043703-CE1005AD-4962-4A07-8C30-19593BFCA375Q35107102-9BBD6D83-FA0F-4033-970C-222AA9F387B1Q35496778-61F1E8F7-FFA1-4235-9289-11AEAEA7CEC9Q35634151-E608D5A0-4442-4E0E-9A33-80EDDEC066C5Q35646110-656EEB08-54DB-48EE-A5C6-3FCB60DDD97AQ35683448-132073B4-51EE-4FE0-844E-87BB74CB8DD7Q35742306-B75838A6-E260-4801-B3AC-6CB5D8A86947Q35905296-F15712E9-5E07-42EC-9662-3CCA3245FD4DQ36080739-2736E8C6-05A3-4AB6-AEE7-A3D2635AC8B7Q36182874-E142FBDB-D264-41DC-84E6-ACD6B90EC7A4Q36294187-C16E1530-83C3-4665-B3C7-113691C19FB8Q36347762-13F9B40F-B3D7-44CC-BF00-4BDC7AC81A68Q36376105-B8DB2714-7CE6-40AF-9201-52FB6FF4ACDCQ36414483-3B6CF8FE-120B-4E67-AD7C-C17D8EFC20CCQ36553571-CBA42FA0-DEBE-416B-953D-FB7CB33A699C
P2860
Biochemical and molecular mechanisms of action of bisphosphonates.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Biochemical and molecular mechanisms of action of bisphosphonates.
@en
Biochemical and molecular mechanisms of action of bisphosphonates.
@nl
type
label
Biochemical and molecular mechanisms of action of bisphosphonates.
@en
Biochemical and molecular mechanisms of action of bisphosphonates.
@nl
prefLabel
Biochemical and molecular mechanisms of action of bisphosphonates.
@en
Biochemical and molecular mechanisms of action of bisphosphonates.
@nl
P2093
P1433
P1476
Biochemical and molecular mechanisms of action of bisphosphonates
@en
P2093
Fraser P Coxon
Jukka Mönkkönen
Julie C Crockett
P356
10.1016/J.BONE.2010.11.008
P577
2010-11-26T00:00:00Z